MetLife
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +17.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 1.7% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 14:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation A
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 12.5x | Better than 68% |
| Forward P/E | 10.1x | Better than 80% |
| Price / Sales | 0.8x | Better than 83% |
| P/E vs own 5-yr range | 29th pctl | Better than 78% |
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 3.9% | Better than 42% |
| Net income CAGR (3Y) | -13.8% | Better than 23% |
| Free cash flow CAGR (3Y) | 9.4% | Better than 52% |
Profitability B-
How much profit the business keeps from each dollar of sales and capital.
| Net margin | 4.2% | Better than 41% |
| Return on equity | 11.4% | Better than 57% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 1.4% | Better than 77% |
| 6-month return | 14.5% | Better than 77% |
| 12-month return (ex latest month) | 34.4% | Better than 73% |
| Distance below 52-week high | 10.4% | Better than 82% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Debt to assets | 2.7% | Better than 85% |
| Interest coverage | 5.4x | Better than 58% |
| Free cash flow / net income | 505.8% | Better than 93% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 91.7% | Better than 75% |
| Upside to average target | 19.7% | Better than 32% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 97.60
- Open
- 97.88
- Day range
- 95.22 - 99.39
- Avg price
- 96.72
- Volume
- 4.31M
- Turnover
- 416.89M
- Turnover ratei
- 0.82%
- Volume ratioi
- 1.21
- Amplitudei
- 4.27%
- 52-week rangei
- 66.02 - 106.72
Valuation
- P/Ei
- 20.31
- P/E (TTM)i
- 12.51
- P/Bi
- 2.71
- EPSi
- 4.71
- Book value / shi
- 35.37
- Net profit
- 2.96B
- Net assets
- 22.23B
Share structure
- Market cap
- 60.12B
- Float capi
- 50.29B
- Shares out
- 628.44M
- Float sharesi
- 525.71M
Dividend & listing
- Div yield (TTM)i
- 2.43%
- Dividend (TTM)
- 2.32
- Listing date
- 2000-04-05
10.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.87M net over the window
Short interest
- Shares short
- 10.75M
- % of floati
- 1.69%
- Days to coveri
- 3.43
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of MetLife (MET)?
MetLife last traded at 95.67. This page shows a periodic quote snapshot. Check the displayed quote time.
What is MetLife's market cap?
About 60.12B.
What is the P/E ratio of MetLife?
The trailing twelve-month P/E is 12.51, below its own 5-year average of 17.05 — toward the bottom of its historical range (28.69% percentile). See the Valuation tab for the full history.
Does MetLife pay a dividend?
Yes. The trailing dividend yield is 2.43%. The 2025 payout was up 4.3% from 2024. See the Dividends tab for the full payment history.
Is MetLife a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 114.55, which implies 19.7% upside from the current price. This is not investment advice.
What is MetLife's StockVane Quant Rating?
The StockVane Momentum strategy currently rates MetLife a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
MetLife discussion 0 comments